A researcher in Purdue University’s College of Science is developing a patent-pending platform technology that mimics the dual-layer structure of viruses to deliver nucleic acid (NA)-based therapies to targeted cancer cells.

David Thompson leads a team developing the carrier system called LENN.

He is a professor in the James Tarpo Jr. and Margaret Tarpo Department of Chemistry and on the faculty of the Purdue Institute for Cancer Research and the Purdue Institute for Drug Discovery.

“LENN comprises two protective layers. The inner shell condenses the nucleic acid; the outer shell protects it from the immune system so it can circulate freely and target cancer cells,” he said.

“We’re mimicking the strategies of viral particles that have been doing this effectively for millions of years.”

Thompson and his team, including postdoctoral researcher Aayush Aayush, used LENN to deliver NA-based therapies to bladder cancer cells.

Their research has been published in the peer-reviewed journal Biomacromolecules.

“The data shows our agile nanocarrier is flexible in its targeting ability, cargo size and disassembly kinetics,” Aayush said.

“It provides an alternative route for nucleic acid delivery using a biomanufacturable, biodegradable, biocompatible and highly tunable vehicle capable of targeting a variety of cells depending on their tumor-specific surface markers.”

Thompson disclosed the system to the Purdue Innovates Office of Technology Commercialization, which has applied for patents to protect the intellectual property. Industry partners interested in developing or commercializing LENN should contact Joe Kasper, assistant director of business development and licensing — life sciences, at jrkasper@prf.org, about track code 70252.

Structure of the Purdue nanocarrier system

Thompson said nucleic acid-based therapies are revolutionizing biomedical research through their ability to control cellular functions at the genetic level. Therapies comprising several constructs are being explored to expand the druggable sites of the human genome.

“Unfortunately, estimates suggest that only 1% or less of the NA cargo that enters the cell gets to the cytosol where it is active,” he said.

“That is one of the motivations for developing this new approach: borrowing design principles from viruses, biological machines that have been delivering cargo to cells for millions of years. Our nonviral delivery system protects and efficiently releases the NA therapies within the cytoplasm of target cells.”

The inner core of the LENN system is made from a complex of nucleic acids and modified cyclodextrins — a product of corn processing.

Its outer core is elastin, one of the most abundant proteins in the body.

Thompson said the design provides several benefits.

“Because elastin is so widely abundant, there are no known antibodies to it. From a drug delivery perspective, that is attractive because the body’s immune system will not recognise it as a foreign nanoparticle,” he said.

“LENN also can deliver cargo as short as silencing RNA, which are 19 or 20 nucleotides long, and as long as huge plasmids exceeding 5,000 base pairs in length.”

Thompson said the LENN system can be made in a biomanufacturable manner.

“All of the building blocks are made from renewable resources: cyclodextrin (from corn) and the elastin-like polypeptide from bacterial fermentation,” he said. “This is in contrast to most traditional pharmaceuticals that are derived from petroleum.”

Validation and next development steps

Thompson said earlier efforts for delivering NA therapies have employed lipid or polymer-based vehicles.

“Unfortunately, those approaches suffer from very low efficiencies, rapid immune system clearance and poor shelf stability,” he said.

“Chemically modified nucleic acids are showing some promise in experimental systems; however, the safety of that approach has not yet been clinically demonstrated.”

The recent Biomacromolecules publication complements four previously published papers based on Thompson’s research on the LENN system components.

“These earlier papers in Biomaterials Science, Oncotarget and Biomacromolecules show the effectiveness of our method to rapidly purify elastin-like polypeptides for use in biomedical applications and its ability to retain function of attached targeting proteins and enzymes,” he said.

“Two of those papers show the specific case of targeting to bladder tumour cells and the other shows that the material purified by our patent-pending technology is capable of targeting human bladder tumours in human and canine surgical samples.”

Thompson said bladder cancer is the first target of the LENN system, but he and his team are developing efforts in other cancer types to explore the scope of the technology.

“We are learning to work with the materials and to optimise them,” he said.

“A bladder cancer therapy is a more localised therapeutic approach than would be needed for developing a subcutaneous or IV injection. However, our plans include walking up that difficulty scale to impact other cancer types.”

The Purdue Institute for Cancer Research provided funding to Thompson to develop and validate LENN.

“This work would still be an idea on a whiteboard if it weren’t for the seed grant from the institute,” he said.

Andrew Mesecar is the Robert Wallace Miller Director of the Purdue Institute for Cancer Research and Distinguished Professor of Biochemistry.

“Professor Thompson continues to be a leading innovator in cancer research. Our institute’s mission is to support basic discovery that lays the foundation of innovative cancer solutions, like his,” he said.

“As a National Cancer Institute-designated cancer center, we make significant contributions to emerging technologies, like our seed funding to support David’s research into LENN. When David and other Purdue researchers discover these innovative solutions and develop them, they have the potential to impact people’s lives around the world.”

Source: Purdue University